Thompson Siegel & Walmsley LLC Sells 434 Shares of Danaher Co. (NYSE:DHR)

Thompson Siegel & Walmsley LLC trimmed its holdings in shares of Danaher Co. (NYSE:DHR) by 2.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,561 shares of the conglomerate’s stock after selling 434 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in Danaher were worth $5,387,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Patrick M Sweeney & Associates Inc. increased its position in shares of Danaher by 3.4% during the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after purchasing an additional 40 shares during the last quarter. Trust Co of Kansas raised its position in Danaher by 4.1% during the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock worth $255,000 after acquiring an additional 40 shares in the last quarter. Abacus Planning Group Inc. lifted its stake in Danaher by 0.7% in the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after acquiring an additional 40 shares during the last quarter. ST Germain D J Co. Inc. grew its position in shares of Danaher by 1.4% in the 1st quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock valued at $719,000 after acquiring an additional 41 shares during the period. Finally, Premier Path Wealth Partners LLC increased its stake in shares of Danaher by 1.8% during the 2nd quarter. Premier Path Wealth Partners LLC now owns 2,345 shares of the conglomerate’s stock worth $586,000 after purchasing an additional 42 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 0.6 %

Shares of Danaher stock opened at $274.25 on Monday. The firm’s 50-day moving average price is $264.55 and its two-hundred day moving average price is $256.51. The company has a market capitalization of $198.07 billion, a price-to-earnings ratio of 46.48, a PEG ratio of 4.48 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company’s revenue was down 2.9% on a year-over-year basis. During the same period in the previous year, the business earned $2.05 earnings per share. On average, analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.39%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Buying and Selling at Danaher

In other news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock worth $11,042,433 over the last 90 days. Insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on DHR shares. Barclays lifted their price target on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 24th. Royal Bank of Canada reissued an “outperform” rating and set a $300.00 target price on shares of Danaher in a report on Friday, September 6th. Leerink Partners raised their price target on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Wells Fargo & Company began coverage on shares of Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective on the stock. Finally, Bank of America lifted their target price on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.